The old transition periods have ended; they are not 2026 purchasing windows. FDA’s reconsidered tirzepatide determination is dated December 19, 2024. Its semaglutide injection shortage-resolution determination is dated February 21, 2025. These are national shortage determinations, not assurances that every local pharmacy has every presentation available. Tirzepatide determination; semaglutide determination. (fda.gov)
FDA’s published updates establish the following historical endpoints for the shortage-dependent enforcement-discretion periods:
| Product | Section 503A | Section 503B |
|---|---|---|
| Tirzepatide injection | Ended following the March 5, 2025 preliminary-injunction denial | March 19, 2025 |
| Semaglutide injection | Ended following the April 24, 2025 preliminary-injunction denial | May 22, 2025 |
These dates concern specified shortage-dependent violations; they were never an exemption from all quality or other statutory requirements. FDA’s consolidated policy updates. (fda.gov)
Did the appeals restore shortage-era permissions?
The appellate opinions located do not restore them. The Fifth Circuit affirmed the district-court judgments in case 25-10600, concerning tirzepatide, and case 25-10758, concerning semaglutide. Both opinions were initially filed August 27, 2026; the semaglutide opinion was revised September 1. Tirzepatide opinion; semaglutide opinion. (ca5.uscourts.gov)
Buyer action: if a supplier says litigation permits continued supply, request the case number, operative order, protected parties, covered conduct and effective dates. Have counsel verify subsequent docket activity. This review did not independently establish the complete mandate, rehearing or Supreme Court petition history, so it does not describe every possible litigation avenue as exhausted.
Explore the table row by row
A working view of the research
Tirzepatide injection
- Section 503A
- Ended following the March 5, 2025 preliminary-injunction denial
- Section 503B
- March 19, 2025
Sources cited on this page
- fda.gov · Source 1 ↗https://www.fda.gov/media/184606/download?attachment=
- fda.gov · Source 2 ↗https://www.fda.gov/media/185526/download?attachment=
- fda.gov · Source 3 ↗https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize
- ca5.uscourts.gov · Source 4 ↗https://www.ca5.uscourts.gov/opinions/unpub/25/25-10600.0.pdf
- ca5.uscourts.gov · Source 5 ↗https://www.ca5.uscourts.gov/opinions/unpub/25/25-10758.0.pdf